Events

New tech brings new hope in our new normal w/ Joanna Shields, WeAreTechWomen

26 JUNE 2020 | VIRTUAL EVENT

Abstract

In recent months the coronavirus pandemic has thrust our global society into a ‘new normal’ which has served as a powerful reminder of the fragile nature of life and health. However, we possess a powerful ally to fight back — AI. In this talk, Joanna Shields will demonstrate how human intelligence partnered with technology promises to accelerate new discoveries, new treatments, and new hope for patients.

Joanna Shields

Joanna Shields (Baroness Shields OBE) is a tech industry veteran with a successful track record building some of the world’s best-known companies. Her career spans over 30 years and has focussed on harnessing the power of technology to drive change that improves connectivity, humanity and society. Prior to joining BenevolentAI, Joanna served as the UK’s first Minister for Internet Safety and Security, Under Secretary of State, Special Advisor on the Digital Economy, and Chair & CEO of TechCityUK.  Before her government service, Joanna held executive roles at Google, Facebook, Bebo/Aol, Decru, RealNetworks, Veon and EFI and served as a non-executive director of the London Stock Exchange Group and TalkTalk Telecom Group.

Joanna founded WePROTECT.org, a multi-stakeholder global alliance working to protect children from online abuse and exploitation. She is a member of the Council on Foreign Relations, the Transatlantic Commission on Election Integrity and the Child Dignity Alliance. In 2014, Joanna was appointed OBE for services to digital industries and voluntary service to young people and made a Life Peer of the House of Lords.

REGISTER >

More Posts

You Might Also Like

Blog
Transforming drug discovery with AI: how we’re building and nurturing the best talent for the job
At BenevolentAI, we are on a mission to bring life-changing medicines to patients, and we are looking for collaborative, mission-driven people to join our tech, drug discovery and business operations teams in London, Cambridge and New York.
Oct 17, 2021
News
BenevolentAI identifies novel target for ulcerative colitis and advances candidate to IND/CTA-enabling studies
BenevolentAI’s AI-Drug Discovery platform uncovered a novel target not previously linked to ulcerative colitis and advanced candidate to preclinical studies.
Oct 14, 2021
Blog
Measuring bias: moving towards more inclusive health research outcomes #stateofai
Having shared our open-source Diversity Analysis Tool last year, we were tasked to investigate and demonstrate the lack of diversity in biomedical data as part of the State of AI Report 2021.
Oct 12, 2021
Blog
Expert-augmented computational drug discovery for rare diseases
Combining scientific expertise, computational tools and our AI-enhanced biomedical knowledge graph to successfully uncover a new drug combination for treating a rare brain cancer in children.
Sep 28, 2021
News
BenevolentAI appoints Dr John Orloff to its Board of Directors
Biopharmaceutical veteran Dr John Orloff joins the BenevolentAI Board as a Non-Executive Director as it scales the development of its leading AI-derived drug pipeline.
Sep 9, 2021
Blog
AI in Drug Discovery
This blog seeks to demystify the application of artificial intelligence (AI) and machine learning (ML) in drug discovery by exploring some of the challenges, opportunities and progress that has been achieved in the field so far.
Jul 13, 2021